Home Cart 0 Sign in  

[ CAS No. 1383716-46-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1383716-46-8
Chemical Structure| 1383716-46-8
Structure of 1383716-46-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1383716-46-8 ]

Related Doc. of [ 1383716-46-8 ]

Alternatived Products of [ 1383716-46-8 ]

Product Details of [ 1383716-46-8 ]

CAS No. :1383716-46-8 MDL No. :MFCD31718218
Formula : C21H25N7O Boiling Point : -
Linear Structure Formula :- InChI Key :XJTIGGCBXFIZJV-UHFFFAOYSA-N
M.W : 391.47 Pubchem ID :67983918
Synonyms :
VPS34 inhibitor 1;Compound 19;PIK-III analogue

Calculated chemistry of [ 1383716-46-8 ]

Physicochemical Properties

Num. heavy atoms : 29
Num. arom. heavy atoms : 18
Fraction Csp3 : 0.38
Num. rotatable bonds : 8
Num. H-bond acceptors : 6.0
Num. H-bond donors : 3.0
Molar Refractivity : 112.6
TPSA : 108.74 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -6.83 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.97
Log Po/w (XLOGP3) : 2.61
Log Po/w (WLOGP) : 2.95
Log Po/w (MLOGP) : 0.92
Log Po/w (SILICOS-IT) : 2.74
Consensus Log Po/w : 2.44

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.84
Solubility : 0.0562 mg/ml ; 0.000144 mol/l
Class : Soluble
Log S (Ali) : -4.54
Solubility : 0.0112 mg/ml ; 0.0000286 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -7.26
Solubility : 0.0000216 mg/ml ; 0.0000000551 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.52

Safety of [ 1383716-46-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1383716-46-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1383716-46-8 ]

[ 1383716-46-8 ] Synthesis Path-Upstream   1~7

  • 1
  • [ 1383716-87-7 ]
  • [ 44838-96-2 ]
  • [ 1383716-46-8 ]
YieldReaction ConditionsOperation in experiment
39% With potassium carbonate In N,N-dimethyl-formamide at 120℃; for 2 h; Preparation of l-(4'-(cyclopropylmethyl)-2-(pyridin-4-ylamino)-4,5'-bipyrimidiii-2'- ylamino)-2-methylpropan-2-ol (1 Ot) : (10t)To a solution of (Z)-l-cyclopropyl-4-(dimethylamino)-3-(2-(pyridin-4- ylamino)pyrimidin-4-yl)but-3-en-2-one (9) (50 mg, 0.155 mmol) in DMF (1288 μ), l-(2- hydroxy-2-methylpropyl)guanidine and potassium carbonate (107 mg, 0.773 mmol) were added and the reaction mixture was stirred at 120°C for 2 hours. The crude product was purified by reverse-phase HPLC [30-90percent organic phase over 15 minutes] followed by Biotage.(TM). silica gel chromatography [10 g SNAP column, 100percent DCM to 12percentMeOH/DCM] to obtain the desired product (23.8mg, 39percent).
Reference: [1] Patent: WO2012/85815, 2012, A1, . Location in patent: Page/Page column 65-66
[2] ACS Medicinal Chemistry Letters, 2016, vol. 7, # 1, p. 72 - 76
  • 2
  • [ 14001-63-9 ]
  • [ 1383716-46-8 ]
Reference: [1] ACS Medicinal Chemistry Letters, 2016, vol. 7, # 1, p. 72 - 76
[2] Patent: WO2012/85815, 2012, A1,
  • 3
  • [ 227322-00-1 ]
  • [ 1383716-46-8 ]
Reference: [1] ACS Medicinal Chemistry Letters, 2016, vol. 7, # 1, p. 72 - 76
[2] Patent: WO2012/85815, 2012, A1,
  • 4
  • [ 1383716-85-5 ]
  • [ 1383716-46-8 ]
Reference: [1] ACS Medicinal Chemistry Letters, 2016, vol. 7, # 1, p. 72 - 76
[2] Patent: WO2012/85815, 2012, A1,
  • 5
  • [ 1383716-86-6 ]
  • [ 1383716-46-8 ]
Reference: [1] Patent: WO2012/85815, 2012, A1,
[2] ACS Medicinal Chemistry Letters, 2016, vol. 7, # 1, p. 72 - 76
  • 6
  • [ 1383716-74-2 ]
  • [ 1383716-46-8 ]
Reference: [1] ACS Medicinal Chemistry Letters, 2016, vol. 7, # 1, p. 72 - 76
[2] Patent: WO2012/85815, 2012, A1,
  • 7
  • [ 504-24-5 ]
  • [ 1383716-46-8 ]
Reference: [1] Patent: WO2012/85815, 2012, A1,
Same Skeleton Products
Historical Records